CNSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 47 cases where CNSP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors.
Industry Biotechnology